UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                      Washington, D.C. 20549

                           FORM 10-KSB

[X]  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the fiscal year ended December 31, 2004

[_]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES
     AND EXCHANGE ACT OF 1934

                 Commission file number 000-32363


                       CANCER CAPITAL CORP.
       ----------------------------------------------------
      (Exact name of registrant as specified in its charter)

            Nevada                                  91-1803648
    -----------------------             ----------------------------------
   (State of incorporation)            (I.R.S. Employer Identification No.)


2157 S. Lincoln Street, Salt Lake City, Utah              84106
--------------------------------------------            ----------
(Address of principal executive offices)                (Zip code)

Issuer's telephone number, including area code: (801) 323-2395

Securities registered pursuant to Section 12(b) of the Act: None.
Securities registered pursuant to Section 12(g) of the Act: Common Stock

The issuer (1) filed all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports) and
(2) has been subject to such filing requirements for the past 90 days.
Yes [X]  No [_]

Disclosure of delinquent filers in response to item 405 of Regulation S-B is
not contained herein, and will not be contained, to the best of registrant's
knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-KSB or any amendment to this Form
10-KSB. [X]

State issuer's revenue for its most recent fiscal year: None

As of March 3, 2005 the registrant had 6,150,000 shares of common stock
outstanding.  A market value of the 4,050,000 shares of voting stock held by
non-affiliates can not be determined because the registrant does not have an
active trading market.

Documents incorporated by reference: None.

Transitional Small Business Disclosure Format: Yes [_] No [X]

<PAGE>


                        TABLE OF CONTENTS

                              PART I

Item 1.  Description of Business.............................................3
Item 2.  Description of Property.............................................5
Item 3.  Legal Proceedings...................................................5
Item 4.  Submission of Matters to a Vote of Security Holders.................5

                             PART II

Item 5.  Market for Common Equity and Related Stockholder Matters............5
Item 6.  Plan of Operation...................................................6
Item 7.  Financial Statements................................................7
Item 8.  Changes In and Disagreements with Accountants on Accounting and
         Financial Disclosure...............................................17
Item 8A. Controls and Procedures............................................17
Item 8B. Other Information..................................................17

                             PART III

Item 9.  Directors, Executive Officers, Promoters and Control Persons,
         Compliance with Section 16(a) of the Exchange Act..................17
Item 10. Executive Compensation.............................................18
Item 11. Security Ownership of Certain Beneficial Owners and Management
         and Related Stockholder Matters....................................18
Item 12. Certain Relationships and Related Transactions.....................19
Item 13. Exhibits...........................................................19
Item 14. Principal Accountant Fees and Services.............................19
Signatures..................................................................21


In this annual report references to "Cancer Capital," "we," "us," and "our"
refer to Cancer Capitol Corp.


        SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

The Securities and Exchange Commission ("SEC") encourages companies to
disclose forward-looking information so that investors can better understand
future prospects and make informed investment decisions.  This report contains
these types of statements.  Words such as "may," "will," "expect," "believe,"
"anticipate," "estimate," "project," or "continue" or comparable terminology
used in connection with any discussion of future operating results or
financial performance identify forward-looking statements.  You are cautioned
not to place undue reliance on the forward-looking statements, which speak
only as of the date of this report.  All forward-looking statements reflect
our present expectation of future events and are subject to a number of
important factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.


                                2


<PAGE>

                              PART I
                              ------

ITEM 1. DESCRIPTION OF BUSINESS

Historical Development

We were incorporated in the state of Nevada on April 11, 1997, to develop an
alternative medical waste treatment and processing equipment system.  We were
unsuccessful in our efforts and are inactive at this time.

Our Plan

We are a development stage company and have had recurring operating losses for
the past two fiscal years.  Our independent auditors have expressed doubt that
we can continue as a going concern unless we obtain financing to continue
operations.

Our business plan is to seek, investigate, and, if warranted, acquire an
interest in a business opportunity.  Our acquisition of a business opportunity
may be made by merger, exchange of stock, or otherwise.  We have very limited
sources of capital, and we probably will only be able to take advantage of one
business opportunity. As of thee date of this filing we have not identified
any business opportunity that we plan to pursue, nor have we reached any
preliminary or definitive agreements or understandings with any person
concerning an acquisition or merger.

 Based on current economic and regulatory conditions, management believes that
it is possible, if not probable, for a company like ours, without many assets
or liabilities, to negotiate a merger or acquisition with a viable private
company.  The opportunity arises principally because of the high legal and
accounting fees and the length of time associated with the registration
process of "going public."  However, should any of these conditions change, it
is very possible that there would be little or no economic value for anyone
taking over control of Cancer Capital.

Our search for a business opportunity will not be limited to any particular
geographical area or industry and includes both U.S. and international
companies.  Our management has unrestricted discretion in seeking and
participating in a business opportunity, subject to the availability of such
opportunities, economic conditions and other factors.  Our management believes
that companies who desire a public market to enhance liquidity for current
stockholders or plan to acquire additional assets through issuance of
securities rather than for cash, will be potential merger or acquisition
candidates.

The selection of a business opportunity in which to participate is complex and
extremely risky and will be made by management in the exercise of its business
judgement.  Our activities are subject to several significant risks which
arise primarily as a result of the fact that we have no specific business and
may acquire or participate in a business opportunity based on the decision of
management which will, in all probability, act without consent, vote, or
approval of our stockholders.  We can not assure you that we will be able to
identify and acquire any business opportunity which will ultimately prove to
be beneficial to Cancer Capital and our stockholders.  Should a merger or
acquisition prove unsuccessful, it is possible management may decide not to
pursue further acquisition activities and management may abandon its
activities and we may become dormant or be dissolved.

It is possible that the range of business opportunities that might be
available for consideration by us could be limited by the fact that our common
stock is not listed on any market.  We cannot assure that a market will
develop or that a stockholder will be able to liquidate his investments
without considerable delay, if at all.  If a market develops, our shares will
likely be subject to the rules of the Penny Stock Suitability Reform Act of
1990.  The liquidity of penny stock is affected by specific disclosure
procedures required by this Act to be followed by all broker-dealers,
including but not limited to, determining the suitability of the stock for a
particular customer, and obtaining a written agreement from the customer to
purchase the stock.  This rule may affect the ability of broker-dealers to
sell our securities and may affect the ability of purchasers to sell our
securities in any market.


                                3

<PAGE>

Investigation and Selection of Business Opportunities

We anticipate that business opportunities will come to our attention from
various sources, including our officers and directors, our stockholders,
professional advisors such as attorneys and accountants, securities
broker-dealers, investment banking firms, venture capitalists, members of the
financial community and others who may present unsolicited proposals.
Management expects that prior personal and business relationships may lead to
contacts with these various sources.

Our management will analyze the business opportunities; however, none of our
management are professional business analysts.  (See, Part III, Item 9:
Directors, Executive Officers, . . .)  Our management has had limited
experience with acquisitions or mergers of business opportunities and has not
been involved with an initial public offering.  Due to our management's
inexperience with acquisitions and mergers, they may rely on promoters or
their affiliates, principal stockholders or associates to assist in the
investigation and selection of business opportunities.

Certain conflicts of interest exist or may develop between Cancer Capital and
our officers and directors.  Our management has other business interests to
which they currently devote attention, which include their primary employment
and management of other development stage reporting companies.  They may be
expected to continue to devote their attention to these other business
interests although management time should be devoted to our business.  As a
result, conflicts of interest may arise that can be resolved only through
their exercise of judgement in a manner which is consistent with their
fiduciary duties to us.

A decision to participate in a specific business opportunity may be made upon
our management's analysis of:
..      the quality of the business opportunity's management and personnel,
..      the anticipated acceptability of its new products or marketing concept,
..      the merit of its technological changes,
..      the perceived benefit that it will derive from becoming a publicly held
       entity, and
..      numerous other factors which are difficult, if not impossible, to
       analyze through the application of any objective criteria.

No one factor described above will be controlling in the selection of a
business opportunity.  Management will attempt to analyze all factors
appropriate to each opportunity and make a determination based upon reasonable
investigative measures and available data. Potential business opportunities
may occur in many different industries and at various stages of development.
Thus, the task of comparative investigation and analysis of such business
opportunities will be extremely difficult and complex. Potential investors
must recognize that because of our limited capital available for investigation
and management's limited experience in business analysis, we may not discover
or adequately evaluate adverse facts about the opportunity to be acquired.

In many instances, we anticipate that the historical operations of a specific
business opportunity may not necessarily be indicative of the potential for
the future because of the possible need to substantially shift marketing
approaches, significantly expand operations, change product emphasis, change
or substantially augment management, or make other changes.  We will be
dependent upon the owners of a business opportunity to identify any such
problems which may exist and to implement, or be primarily responsible for,
the implementation of required changes.

Form of Acquisition

We cannot predict the manner in which we may participate in a business
opportunity. Specific business opportunities will be reviewed as well as our
needs and desires and those of the promoters of the opportunity.  The legal
structure or method deemed by management to be suitable will be selected based
upon our review and our relative negotiating strength. Such methods may
include, but are not limited to, leases, purchase and sale agreements,
licenses, joint ventures and other contractual arrangements. We may act
directly or indirectly through an interest in a partnership, corporation or
other forms of organizations.  We may be required to merge, consolidate or
reorganize with other corporations or forms of business organizations. In
addition, our present management and stockholders most likely will not have
control of a majority of our voting shares following a merger or
reorganization transaction. As part of such a transaction, our existing
directors may resign and new directors may be appointed without any vote by
our

                                4


<PAGE>

stockholders.

We likely will acquire our participation in a business opportunity through the
issuance of common stock or other securities.  Although the terms of any such
transaction cannot be predicted, it should be noted that issuance of
additional shares also may be done simultaneously with a sale or transfer of
shares representing a controlling interest by current principal stockholders.

In the event we merge or acquire a business opportunity, the successor company
will be subject to our reporting obligations.  This is commonly referred to as
a "back door registration."  A back door registration occurs when a
non-reporting company becomes the successor of a reporting company by merger,
consolidation, exchange of securities, acquisition of assets or otherwise.
This type of event requires the successor company to file a current report
with the SEC which provides the same kind of information about the company to
be acquired that would appear in a registration statement, including audited
and pro forma financial statements.  Accordingly, we may incur additional
expense to conduct due diligence and present the required information for the
business opportunity in any report.  Also, the SEC may elect to conduct a full
review of the successor company and may issue substantive comments on the
sufficiency of disclosure related to the company to be acquired.

Competition

We expect to encounter substantial competition in our effort to locate
attractive opportunities.  Business development companies, venture capital
partnerships and corporations, venture capital affiliates of large industrial
and financial companies, small investment companies, and wealthy individuals
will be our primary competition. Many of these entities will have
significantly greater experience, resources and managerial capabilities than
we do and will be in a better position than we are to obtain access to
attractive business opportunities.  We also will experience competition from
other public development stage companies seeking merger candidates, many of
which may have more funds available for such transactions.

Employees

We currently have no employees.  Our management expects to confer with
consultants, attorneys and accountants as necessary.  We do not anticipate a
need to engage any full-time employees so long as we are seeking and
evaluating business opportunities.

                 ITEM 2. DESCRIPTION OF PROPERTY

We do not currently own or lease any property.  Until we pursue a viable
business opportunity and recognize income, we will not seek independent office
space.

                    ITEM 3. LEGAL PROCEEDINGS

We are not a party to any proceedings or threatened proceedings as of the date
of this filing.

   ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

We have not submitted a matter to a vote of our shareholders during the fourth
quarter of the 2004 fiscal year.


                             PART II
                             -------

ITEM 5: MARKET PRICE FOR COMMON EQUITY, RELATED STOCKHOLDER MATTERS

Market, Holders and Dividends

Our common stock is not listed on a public market as of the date of this
filing.  We have approximately 38

                                5


<PAGE>

stockholders of record holding 6,150,000 common shares.  We have not declared
dividends on our common stock and do not anticipate paying dividends on our
common stock in the foreseeable future.

Recent Sales of Unregistered Securities

None.

Issuer Purchase of Securities

None.

                    ITEM 6.  PLAN OF OPERATION

At December 31, 2004 we had $3,706 cash, total liabilities of $10,160, and we
have experienced losses from inception.  During the next twelve months our
management intends to actively seek an operating company to acquire or merge
with which will create operating revenue.

We currently cannot satisfy our cash requirements for our operations.  The
majority of our operating expenses are related to our reporting obligations
under the Exchange Act.  These expenses are related to legal, accounting and
professional services required to prepare and file our reports with the SEC.
We are unable to pay cash for these services and have relied on related and
third parties to pay for these costs on our behalf.  These parties have not
entered into written agreements guaranteeing advances and, therefore, these
parties are not obligated to provide funds in the future.  However, management
anticipates that these parties will continue to pay for these costs on our
behalf during the next twelve months.  Historically, we have paid for these
advances by converting the debt into common stock.

If we obtain a business opportunity, then it may be necessary to raise
additional capital.  We likely will sell our common stock to raise this
additional capital.  We expect to issue such stock pursuant to exemptions
provided by federal and state securities laws.  The purchasers and manner of
issuance will be determined according to our financial needs and the available
exemptions.  We do not currently intend to make a public offering of our
stock.  We also note that if we issue more shares of our common stock, then
our shareholders may experience dilution in the value per share of their
common stock.

                                6
<PAGE>

                   ITEM 7. FINANCIAL STATEMENTS








                       Cancer Capital Corp.

                       Financial Statements

                    December 31, 2004 and 2003





                                7

<PAGE>



                             CONTENTS


Independent Auditor's Report ............................................F-3

Balance Sheets ..........................................................F-4

Statements of Operations ................................................F-5

Statements of Stockholders' Equity ......................................F-6

Statements of Cash Flows ................................................F-7

Notes to the Financial Statements .......................................F-8



                                8


<PAGE>

   Chisholm,
     Bierwolf &                                 533 West 2600 South, Suite 250
       Nilson, LLC                                       Bountiful, Utah 84010
                                                         Office (801) 292-8756
Certified Public Accountants                                Fax (801) 292-8809

______________________________________________________________________________




                   INDEPENDENT AUDITOR'S REPORT

To the Board of Directors and Stockholders
of Cancer Capital Corp.:

We have audited the accompanying balance sheets of Cancer Capital Corp. (a
development stage company) as of December 31, 2004 and 2003 and the related
statements of operations, stockholders' equity and cash flows for the years
ended December 31, 2004 and 2003 and from inception April 11, 1997 through
December 31, 2004.  These financial statements are the responsibility of the
Company's management.  Our responsibility is to express an opinion on these
financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States).  Those standards require that we
plan and perform the audits to obtain reasonable assurance about whether the
financial statements are free of material misstatement.  An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements.  An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation.  We believe that our
audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Cancer Capital Corp.  (a
development stage company) as of December 31, 2004 and 2003 and the results of
its operations and cash flows for the years ended December 31, 2004 and 2003
and from inception April 11, 1997 through December 31, 2004 in conformity with
generally accepted accounting principles in the United States of America.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern.  The Company has suffered recurring
losses from operations which raises substantial doubt about its ability to
continue as a going concern.  Management's plans in regard to these matters
are described in Note 2.  The financial statements do not include any
adjustments that might result from the outcome of this uncertainty.


/s/ Chisholm, Bierwolf & Nilson

Chisholm, Bierwolf & Nilson
Bountiful, Utah 84010
March 4, 2005

                               F-3
<PAGE> 9



                       Cancer Capital Corp.
                  (A Development Stage Company)
                          Balance Sheets



                              ASSETS
                                                          December 31
                                                  ---------------------------
                                                        2004         2003
                                                  ------------- -------------
CURRENT ASSETS

  Cash (Note 1)                                   $      3,706  $        616
                                                  ------------- -------------

    TOTAL ASSETS                                  $      3,706  $        616
                                                  ============= =============


               LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
  Accounts Payable - related party                $      5,000  $      5,000
  Accounts Payable - other                               5,160             -
                                                  ------------- -------------

    Total Liabilities                                   10,160         5,000

STOCKHOLDERS' EQUITY
  Common Stock, $.001 par value; 20,000,000
    shares authorized; 6,150,000 shares
    issued and outstanding                               6,150         6,150
  Additional Paid in Capital                            47,050        47,050
  Deficit Accumulated during the development stage     (59,654)      (57,584)
                                                  ------------- -------------

    Total Stockholders' Equity (deficit)                (6,454)       (4,384)
                                                  ------------- -------------

    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY    $      3,706  $        616
                                                  ============= =============



The accompanying notes are an integral of these financial statements.

                               F-4
<PAGE> 10

                       Cancer Capital Corp.
                  (A Development Stage Company)
                     Statements of Operations


                                                                From
                                                                Inception on
                                       For the years ended      April 11,
                                          December 31,          1997 to
                                    --------------------------- Dec. 31,
                                         2004         2003      2004
                                    ------------- ------------- -------------

REVENUES                            $          -  $          -  $          -
                                    ------------- ------------- -------------
EXPENSES
  General & Administrative                 2,070        11,245        59,654
                                    ------------- ------------- -------------

    Total Expenses                         2,070        11,245        59,654
                                    ------------- ------------- -------------

Net Loss                            $     (2,070) $    (11,245) $    (59,654)
                                    ============= ============= =============

Net Loss Per Share                  $      (0.00) $      (0.00) $      (0.01)
                                    ============= ============= =============

Weighted average shares outstanding    6,150,000     5,193,836     5,033,658
                                    ============= ============= =============




The accompanying notes are an integral part of these financial statements.

                               F-5
<PAGE> 11


                       Cancer Capital Corp.
                  (A Development Stage Company)
                Statements of Stockholders' Equity
    From Inception on April 11, 1997 through December 31, 2004

                                                                 Deficit
                                                                 Accumulated
                                                     Additional  During the
                                Common Stock         Paid in     Development
                             Shares       Amount     Capital     Stage
                           ------------- ----------- ----------- -------------
Common stock, issued at
 inception for cash at
 $.001 per share              1,000,000  $    1,000  $        -  $          -

Common stock, issued at
 inception for services
 at $.001 per share             200,000         200           -             -

Common stock issued for
 cash at $.01 per share       3,500,000       3,500      31,500             -

Net (loss) for the year
 ended December 31, 1997              -           -           -       (22,400)
                           ------------- ----------- ----------- -------------

Balance - December 31, 1997   4,700,000       4,700      31,500       (22,400)

Net (loss) for the year
 ended December 31, 1998              -           -           -        (9,900)
                           ------------- ----------- ----------- -------------

Balance - December 31, 1998   4,700,000       4,700      31,500       (32,300)

Net (loss) for the year
 ended December 31, 1999              -           -           -        (1,300)
                           ------------- ----------- ----------- -------------

Balance - December 31, 1999   4,700,000       4,700      31,500       (33,600)

Common stock issued for
 services at $.01 per share     200,000         200       1,800             -

Common stock issued for
 services at $.02 per share     250,000         250       4,750             -

Net (loss) for the year
 ended December 31, 2000              -           -           -        (7,600)
                           ------------- ----------- ----------- -------------

Balance - December 31, 2000   5,150,000       5,150      38,050       (41,200)

Net (loss) for the year
 ended December 31, 2001              -           -           -             -
                           ------------- ----------- ----------- -------------

Balance - December 31, 2001   5,150,000       5,150      38,050       (41,200)

Net (loss) for the year
 ended December 31, 2002              -           -           -        (5,139)
                           ------------- ----------- ----------- -------------

Balance - December 31, 2002   5,150,000       5,150      38,050       (46,339)

Common stock issued for
 services at $.01 per share   1,000,000       1,000       9,000             -

Net (loss) for the year
  ended December 31, 2003             -           -           -       (11,245)
                           ------------- ----------- ----------- -------------

Balance - December 31, 2003   6,150,000       6,150      47,050       (57,584)

Net (loss) for the year
  ended December 31, 2004             -           -           -        (2,070)
                           ------------- ----------- ----------- -------------

Balance - December 31, 2004   6,150,000  $    6,150  $   47,050  $    (59,654)
                           ============= =========== =========== =============








The accompanying notes are an integral part of these financial statements.

                               F-6

<PAGE> 12



                       Cancer Capital Corp.
                  (A Development Stage Company)
                     Statements of Cash Flows
                                                                From
                                                                Inception on
                                       For the years ended      April 11,
                                          December 31,          1997 through
                                    --------------------------- December 31,
                                         2004         2003      2004
                                    ------------- ------------- -------------
Cash Flows from Operating Activities

  Net Loss                          $     (2,070) $    (11,245) $    (59,654)
  Adjustments for non-cash items:
    Increase in Accounts Payable           5,160             -        10,160
    Shares issued for services                 -        10,000        17,200
                                    ------------- ------------- -------------
  Net Cash Provided (Used) by
  Operating Activities                     3,090        (1,245)      (32,294)
                                    ------------- ------------- -------------

Cash Flows from Investing Activities:          -             -             -
                                    ------------- ------------- -------------
  Net Cash Provided (Used) in
  Investing Activities                         -             -             -
                                    ------------- ------------- -------------
Cash Flows from Financing Activities:
  Issued common stock for cash                 -             -        36,000
                                    ------------- ------------- -------------
  Net cash Provided by
  Financing Activities                         -             -        36,000
                                    ------------- ------------- -------------

Increase (Decrease) in Cash                3,090        (1,245)        3,706

Cash - beginning of period                   616         1,861             -
                                    ------------- ------------- -------------

Cash - end of period                $      3,706  $        616  $      3,706
                                    ============= ============= =============
Supplemental Cash Flow Information:

  Cash Paid For:
    Interest                        $          -  $          -  $          -
    Income Taxes                    $          -  $          -  $          -

NonCash Financing Activities

  During 1997, 200,000 shares of common stock were issued at $.001 per
   share for services

  During 2000, 200,000 and 250,000 shares of common stock were issued
   for services at $.01 and $.02 per share, respectively

  During 2003, 1,000,000 shares of common stock were issued for services
   at $.01 per share


The accompanying notes are an integral part of these financial statements.

                               F-7

<PAGE> 14


                       Cancer Capital Corp.
                  (A Development Stage Company)
                Notes to the Financial Statements
                    December 31, 2004 and 2003

NOTE 1 - Summary of Significant Accounting Policies

a.  Organization & Consolidation Policy

Cancer Capital Corp. (the Company), was incorporated April 11, 1997 under the
laws of the State of Nevada.   The Company was originally formed for the
purpose of developing an alternative medical waste treatment system.  However,
the Company in December 1997 abandoned this purpose and has since been
inactive.  The Company has never commenced any significant activities or
secured operations.  The Company is currently searching for other business
opportunities and is in the development stage according to Financial
Accounting Standards Board Statement No. 7.

b.  Accounting Method

The Company recognizes income and expense on the accrual basis of accounting.

c.  Earnings (Loss) Per Share

                                        Income (loss)   Shares     Per Share
                                         (Numerator) (Denominator)   Amount
                                        ------------ ------------- ----------
For the year ended December 31, 2004:

 Basic EPS
  Income (loss) to common stockholders  $   ( 2,070)    6,150,000  $   (0.00)
                                        ============ ============= ===========
For the year ended December 31, 2003:

 Basic EPS
  Income (loss) to common stockholders  $   (11,245)    5,193,836  $   (0.00)
                                        ============ ============= ==========
From inception on April 11, 1997 to
 December 31, 2004:

 Basic EPS
  Income (loss) to common stockholders  $   (59,654)    5,033,658  $   (0.01)
                                        ============ ============= ==========

The computation of earnings per share of common stock is based on the weighted
average number of shares outstanding at the date of the financial statements.

d.  Cash and Cash Equivalents

The Company considers all highly liquid investments with maturities of three
months or less to be cash equivalents.




                               F-8
<PAGE> 14


                       Cancer Capital Corp.
                  (A Development Stage Company)
                Notes to the Financial Statements
                    December 31, 2004 and 2003

NOTE 1 - Summary of Significant Accounting Policies (continued)

e.  Provision for Income Taxes

No provision for income taxes have been recorded due to net operating loss
carryforwards totaling approximately $59,654 which will be offset against
future taxable income.  These NOL carryforwards began to expire in the year
2017  No tax benefit has been reported in the financial statements because the
Company believes there is a 50% or greater chance the carryforward will expire
unused.

Deferred tax asset and the valuation account is as follows as December 31,
2004 and 2003:
                                                       December 31,
                                                  2004           2003
                                               ------------- -------------
Deferred tax asset:
   NOL carryforward                            $     20,282  $     19,579

   Valuation allowance                              (20,282)      (19,579)
                                               ------------- -------------

                                               $          -  $          -
                                               ============= =============

f.  Use of estimates

The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates.

NOTE 2 - Going Concern

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern.  The Company has minimal assets and
has had recurring operating losses for the past several years and is dependent
upon financing to continue operations.  The financial statements do not
include any adjustments that might result from the outcome of this
uncertainty.  It is management's plan to find an operating company to merge
with, thus creating necessary operating revenue.

NOTE 3 - Development Stage Company

The Company is a development stage company as defined in Financial Accounting
Standards Board Statement No. 7.  It is concentrating substantially all of its
efforts in raising capital and defining its business operation in order to
generate significant revenues.



                               F-9

<PAGE> 15


                       Cancer Capital Corp.
                  (A Development Stage Company)
                Notes to the Financial Statements
                    December 31, 2004 and 2003


NOTE 4 - Related Party Transactions

As of the year ended December 31, 2004, the Company has incurred $5,000 of
professional fees payable to professionals affiliated with First Equity
Holdings Corp.  An officer of the Company is also an employee of First Equity
Holdings Corp.


NOTE 5 - Stockholders' Equity

During 2003, the Company issued 1,000,000 shares of common stock, for services
rendered valued at $10,000 (or $.01 per share).








                               F-10
<PAGE> 16


      ITEM 8. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS
              ON ACCOUNTING AND FINANCIAL DISCLOSURE

In our current report dated February 9, 2004, we reported that our independent
auditors, Chisholm & Associates, Certified Public Accountants, resigned as our
independent auditors and we engaged Chisholm, Bierwolf & Nilson, LLC,
Certified Public Accountants, as our independent auditors .

                ITEM 8A.  CONTROLS AND PROCEDURES

Our President, who acts in the capacity of principal executive officer and
principal financial officer, has reevaluated the effectiveness of our
disclosure controls and procedures as of the end of the period covered by this
report and determined that there continued to be no significant deficiencies
in these procedures.  Also, there were no changes made or corrective actions
to be taken related to our internal control over financial reporting.

                    ITEM 8B. OTHER INFORMATION

None.


                             PART III
                             --------

ITEM 9. DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS,
        COMPLIANCE WITH SECTION 16(a) OF THE EXCHANGE ACT

Directors and Officers

Our executive officers and directors and their respective ages, positions and
biographical information are set forth below.  Our bylaws require two
directors who serve for terms of one year or until they are replaced by a
qualified director.  Our executive officers are chosen by our board of
directors and serve at its discretion.  John and Michelle Peters are married.


Name               Age    Position Held                    Director Since
------------------ ------ -------------------------------- ---------------
John W. Peters      53    President and Director            April 1997
L. Michelle Peters  52    Secretary/Treasurer and Director  April 1997

John W. Peters:  Since July 1999 Mr. Peters has been the manager of
Development Specialties, Inc. a property management company.  Since 1995 to
the present he has been President and Chairman of the Board of Earth Products
and Technologies, Inc, a reporting company.  Prior to 1995 he was employed as
Earth Products' operations manager.  He also is a director of Bingham Canyon
Corporation, Skinovation Pharmaceutical Incorporated and Suncrest Global
Energy Corp., which are development stage reporting companies.  His prior
business experience includes President and Executive Officer of Certified
Environmental Laboratories, Inc. and Vice President of Sales and Marketing for
Comco Communications Corp. in California.  Mr. Peters studied business
administration at Long Beach Community College and California Polytechnic
State University in San Louis Obispo, California.

L. Michelle Peters:  Mrs. Peters has served as our Secretary/Treasurer and as
a Director since our inception.  She has been employed as a legal secretary
for law firms located in Salt Lake City, Utah for the past 20 years.  Mrs.
Peters has over 30 years of experience in the legal profession as a legal
secretary, paralegal and office administrator.

Audit Committee Financial Expert

Because we have minimal operations we do not have an audit committee serving
at this time.  Accordingly, we do not have an audit committee financial expert
serving on an audit committee.


                                17


<PAGE>

Compliance with Section 16(a) of the Exchange Act

Section 16(a) of the Securities Exchange Act of 1934 requires our directors,
executive officers and persons who own more than ten percent of a registered
class of our equity securities, to file with the Securities and Exchange
Commission initial reports of ownership and reports of changes in ownership of
our common stock.  Officers, directors and greater than ten-percent beneficial
owners are required by SEC regulations to furnish us with copies of all
Section 16(a) reports they file.  We believe no filings were required to be
filed during 2004.

Code of Ethics

Due to the fact that we have minimal operations, we have not adopted a code of
ethics for our principal executive and financial officers.  Our board of
directors will revisit this issue in the future to determine if adoption of a
code of ethics is appropriate.  In the meantime, our management intends to
promote honest and ethical conduct, full and fair disclosure in our reports to
the SEC, and compliance with applicable governmental laws and regulations.

                 ITEM 10. EXECUTIVE COMPENSATION

Our named executive officers have not received any cash compensation, bonuses,
stock appreciation rights, long term compensation, stock awards or long-term
incentive rights in excess of $100,000 during the past three fiscal years.
John W. Peters, who acts in the capacity similar to Chief Executive Officer
did not receive any compensation during the year ended December 31, 2004.  We
have not entered into employment contracts with our executive officers and
their compensation, if any, will be determined at the discretion of our Board
of Directors.

Compensation of Directors

We do not have any standard arrangement for compensation of our directors for
any services provided as director, including services for committee
participation or for special assignments.

  ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND
            MANAGEMENT AND RELATED STOCKHOLDER MATTERS

Securities Under Equity Compensation Plans

We do not have any securities authorized for issuance under any equity
compensation plans.

Beneficial Ownership

The following table sets forth the beneficial ownership of our outstanding
common stock by our management and each person or group known by us to own
beneficially more than 5% of our outstanding common stock.  Beneficial
ownership is determined in accordance with the rules of the SEC and generally
includes voting or investment power with respect to securities.  Except as
indicated by footnote, the persons named in the table below have sole voting
power and investment power with respect to all shares of common stock shown as
beneficially owned by them.  The percentage of beneficial ownership is based
upon 6,150,000 shares of common stock outstanding as of March 3, 2005.

                    CERTAIN BENEFICIAL OWNERS
                    -------------------------

Name and Address of                Number of Shares of
Beneficial Owners                  Common Stock          Percentage of Class
--------------------------------   -------------------   -------------------
Compass Equity Partners             500,000               8.1%
369 East 900 South
Salt Lake City, Utah 84111


                                18

<PAGE>

First Equity Holdings Corp.         500,000               8.1%
2157 S. Lincoln Street
Salt Lake City, UT 84106

M. Jeanne Ball                      400,000               6.5%
6071 Aries Drive
Salt Lake City, Utah 84118

Anita Patterson                     400,000               6.5%
588 NO West Capital
Salt Lake City, Utah 84103


                            MANAGEMENT
                           -----------

Name and Address of               Number of Shares of
Beneficial Owners                 Common Stock            Percentage of Class
-------------------------------   ---------------------   -------------------
John W. Peters                      650,000                10.6%
2157 S. Lincoln Street
Salt Lake City, Utah 84106

L. Michelle Peters                  450,000                 7.3%
2157 S. Lincoln Street
Salt Lake City, Utah 84106

All executive officers and
 directors as a group               1,100,000              17.9%



     ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

We have not engaged in any transactions in excess of $60,000 during the past
two years involving our executive officers, directors, 5% or more stockholders
or immediate family members of such persons.


                        ITEM 13. EXHIBITS

No.   Description
----- ----------------------------------------------------------------------
3.1   Articles of Incorporation (Incorporated by reference to exhibit 3.1 of
      Form 10-SB, filed September 18, 2000.)
3.2   Bylaws of  Bingham Canyon (Incorporated by reference to exhibit 3.3 of
      Form 10-SB, filed September 18, 2000.)
31.1  Principal Executive Officer Certification
31.2  Principal Financial Officer Certification
32.1  Section 1350 Certification


         ITEM 14.  PRINCIPAL ACCOUNTANT FEES AND SERVICES

Audit Fees

The aggregate fees billed for each of the last two fiscal years for
professional services rendered by our principal account for the audit of our
annual financial statement and review of financial statements included in
quarterly reports and services normally provided by the accountant in
connection with statutory and regulatory filings or engagements were $1,239
for fiscal year ended 2003 and $1,352 for fiscal year ended 2004.



                                19

<PAGE>

Audit-Related Fees

Our auditor did not bill any fees in each of the last two fiscal years for
assurance and related services by the principal accountant that are reasonably
related to the performance of the audit or review of our financial statements
that are not reported above.

Tax Fees

Our auditor did not bill any fees in each of the last two fiscal years for
professional services rendered by the principal accountant for tax compliance,
tax advise, and tax planning.

All Other Fees

Our auditor did not bill any fees in each of the last two fiscal years for
products and services provided by the principal accountant, other than the
services reported above

Pre-approval Policies

We do not have an audit committee currently serving and as a result our board
of directors performs the duties of an audit committee.  Our board of
directors will evaluate and approve in advance, the scope and cost of the
engagement of an auditor before the auditor renders audit and non-audit
services.  We do not rely on pre-approval policies and procedures.

                                20

<PAGE>


                            SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.



Date: March 25, 2005                   CANCER CAPITAL CORP.


                                       /s/ John W. Peters
                                    By:_______________________________
                                       John W. Peters
                                       President



In accordance with the Exchange Act, this report has been signed below by the
following person on behalf of the registrant and in the capacities and on the
dates indicated.



                                       /s/ John W. Peters
Date: March 25, 2005                   ______________________________________
                                       John W. Peters
                                       Principal Executive Officer
                                       Principal Financial Accounting Officer



                                       /s/ L. Michelle Peters
Date: March 25, 2005                   _____________________________________
                                       L. Michelle Peters
                                       Secretary/Treasurer and Director


                                21